EMA Supports Actos Despite Cancer Risk
The EMA’s Committee for Medicinal Products for Human Use recently reaffirmed that it plans to keep the type 2 diabetes drug on the market in Europe, despite an acknowledgement by the organization that Actos may cause bladder cancer. According to a press release issued by the EMA, the agency’s stance is that Actos, also known as pioglitazone, should still be considered as a valid treatment option for certain patients with type 2 diabetes, but only when other treatments have been deemed unsuitable or have failed to help the patient adequately monitor their condition.
In June, both France and Germany pulled Actos off the shelves after research demonstrated that taking the drug resulted in an increased risk for developing bladder cancer. In July, the EMA recommended the placement of new warning labels advising Actos users of the potential for serious side effects, including bladder cancer. In the United States, the Food and Drug Administration also opted to issue new warning labels for the drug, rather than initiating a full Actos recall.
The Committee’s decision to offer continued support of the sale of Actos on the European market will be sent to the European Commission and will likely be approved by the Standing Committee sometime in the next two to three months.
The EMA’s approval of Actos serves to bolster Japanese pharmaceutical company Takeda, which manufactures the drug. Actos has been a significant moneymaker for the company and Takeda had hoped that the drug would overtake sales of rival heart medication Avandia. Despite the warnings issued by the FDA and those suggested by the EMA, Takeda continues to successfully market and profit from the sales of Actos worldwide.
In the U.S., Actos lawsuits are quickly mounting, with patients alleging a broad range of side effects apart from the incidence of bladder cancer. According to court documents, other alleged Actos side effects include eye cancer macular edema, a condition that can lead to blindness; a worsening of congestive heart failure symptoms in patients who have the disease; and less serious side effects, including shakiness, dizziness, sudden changes in behavior and tingling around the mouth. In the lawsuits alleging that Actos causes bladder cancer, attorneys for the plaintiffs are claiming that Takeda Pharmaceuticals made a concerted effort to cover up the bladder cancer link because of financial incentives.
If you or someone you love has developed bladder cancer, heart failure or another serious condition after taking Actos, you too may have grounds for a personal injury claim. You need to discuss the details of your case with an experienced Actos attorney right away.
The law firm of Nadrich & Cohen investigates Actos side effects claims in all 50 states and is committed to helping individuals who have been injured by the drug get the compensation they’re entitled to. If you think you may have an Actos injury claim, call us today at 1-800-722-0765 to speak with a member of our Actos legal team. We are available to speak with you at no charge and there is never a fee unless we collect a judgment on your behalf. Call now to get the experienced legal representation you need to win your Actos side effects lawsuit.